Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 12/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13814819 | 0.86 | SMN1; SMN2 (0.64) | F2RKMT2ANPC1RAB9ANLRP3 | |
| SCHEMBL13593293 | 0.85 | MEN1 (0.58) | KMT2ANPC1RAB9APPARGPPARA | |
| SCHEMBL10973331 | 0.83 | ITGB3 (0.64) | KMT2ANPC1RAB9APPARGPPARA | |
| SCHEMBL31661819 | 0.82 | ALOX15 (0.64) | KMT2ANPC1RAB9APPARGPPARA | |
| SCHEMBL5668315 | 0.82 | ALOX15 (0.64) | KMT2ANPC1RAB9APPARGPPARA | |
| SCHEMBL29200396 | 0.81 | F2R (0.65) | F2RKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL30802667 | 0.81 | F2R (0.65) | F2RKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL13593299 | 0.81 | ITGB3 (0.62) | KMT2ANPC1RAB9APPARGPPARA | |
| SCHEMBL29200425 | 0.80 | F2R (0.64) | F2RKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL30802666 | 0.80 | F2R (0.64) | F2RKMT2ANPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090324540-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090324540-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324540-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | ABCB4, ABCB7, ALPP | F2R 2281/4885KMT2A 4430/4885NPC1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.